HCA Healthcare

HCA

----

HCA Healthcare

HCA

----

Open: --
High: --
Low: --
Prev. Close: --
Volume: --
Turnover: --
Avg Price: --
Bid/Ask Ratio: --
Amplitude: --
52wk High: --
Volume Ratio: --
Turnover Ratio: --

HCA Healthcare Analyst Rating

Forecast & Rating

Jul 24, 2026

Price forecast

$467.2022.24%

Forecast & RatingBuy

25analysts

Strong buy52.00%
Buy4.00%
Hold40.00%
Sell4.00%
Strong sell0.00%

Daily Events

Jul, 24
HCA Healthcare closed at $382.19, up 1.5% from the previous close of $376.50, on the day of its Q2 earnings release. The stock experienced significant intraday volatility, declining in early morning trading to a low of $364.67 at 07:34 ET amid guidance cut expectations, before surging to an intraday peak of $398.51 at 10:13 ET on strong Q2 results, ultimately settling back toward the closing price. Q2 revenue grew 8.7% year-over-year to approximately $19.2 billion, and earnings per share increased 11% YoY, while the company declared a dividend of $0.78, signaling solid operational momentum. However, management's downward revision of full-year guidance—attributable to payer mix pressures from Medicaid reductions and declining surgical volumes—partially offset the positive earnings surprise. Notably, rival Tenet Healthcare surged 23% the same day, highlighting market differentiation between healthcare service providers. From a valuation perspective, HCA trades at a trailing PE of 12.58 with a market cap of $85.4 billion. The stock is down 18.75% year-to-date and trades 31.33% below its 52-week high of $556.52, currently below both the 20-day moving average of $390.41 and the 60-day moving average of $395.96.
Jul, 23
HCA Healthcare staged a strong rebound to $376.50 today, touching $384 during post-market hours and outperforming healthcare peers. The rally follows a challenging period: the Q2 earnings report triggered a sharp selloff as management cut 2026 profit guidance due to payer mix shifts and elective surgery volume declines, sending shares down over 32% from the 52-week peak of $556.52. Year-to-date decline stands at roughly 20%, with the stock now trading clearly below its 20-day moving average of $390.65 and 60-day average of $396.78. Analysts responded by cutting their price target to $486.6, which still implies about 25% upside from current levels. Today's bounce may reflect a reversal from extreme pessimism—investors appear to view the bad news as substantially priced in—though the fundamental headwinds of depressed surgical volumes and unfavorable payer mix remain unresolved.
Jul, 22
HCA Healthcare traded mixed today with premarket strength failing to persist through the regular session. After rising 0.51% to $375 during premarket, the stock opened at $374.39 and reached an intraday high of $377 at 10:15 ET, but closed at $371.87, down 0.33% from prior close of $373.09, and further weakened to $371.31 in extended hours. Year-to-date performance has been notably weak, with the stock down 20.94% and trading 33.18% below its 52-week high of $556.52. The stock trades significantly below its 20-day moving average of $391.21 and 60-day moving average of $397.94, reflecting technical weakness. The recent decline stems from the company's guidance reduction for 2026 earnings, driven by lower surgical volumes in Q2 and unfavorable payer mix shifts, raising concerns about near-term profitability. Despite solid Q1 2026 fundamentals with EPS of $7.15 (up 10.85% YoY) and revenue of $19.109 billion (up 4.3% YoY), analysts cut their 12-month price target to $486.6, implying only 25% upside from current levels. While the current P/E ratio of 12.24x appears attractive, the recent guidance reduction has dampened investor sentiment and limited near-term recovery catalysts.
Jul, 21
HCA Healthcare bounced to $373.09 on Monday (+0.72% intraday), extending gains to $375 in post-market trading, as investors digested Friday's downturn—when the company slashed 2026 earnings guidance following Q2 surgical volume declines and adverse payer mix shifts. Q1 revenues of $19.1 billion grew 4.3% year-over-year, yet net income barely expanded 0.62%, with net margin compressing from Q4's 9.62% to 8.48%, signaling operational pressure intensifying. Trading at a 12.3x P/E with $83.4 billion market cap, the stock has plummeted 33% from its 52-week high of $556.52 and is down 20.68% year-to-date, languishing below its 20-day and 60-day moving averages. Analysts subsequently trimmed the 12-month price target to $486.6, suggesting residual recovery potential yet underlying headwinds persist.
Jul, 20
HCA Healthcare traded mixed signals on July 20 following its recent Q2 earnings guidance cut, driven by a deteriorating payer mix and softer surgical volumes—indicating potential headwinds for the nation's largest hospital operator. Pre-market trading rallied sharply to $384.58 (+3.6% relative to the prior close), but midday selling pressure subsequently brought the stock down to $368.73 (−0.7%), with the regular session ultimately closing at $370.42, essentially flat versus the prior day. Post-market recovery to $375.58 suggested some bargain-hunting interest. From a technical perspective, the stock has retreated 33% from its March high of $556.52 and trades 21% below year-to-date levels, now positioned below both its 20-day ($392.16) and 60-day ($400.63) moving averages. Following the earnings revision, analysts cut their 12-month price target to $486.6, implying 25% upside potential, though the bull case remains contingent on stabilization in payer demographics and surgical procedure volumes.

News

Posts

Bullish vs. Bearish — Last 3 Months

819 followers · 0 opinions

FHW

▲Bullish50%

50%Bearish▼

D
Dolphin ResearchOct 30, 2025 at 01:18 AM
Google (Minutes): We are the only full-stack AI cloud platform
The following are the FY25 Q3 earnings call minutes for Google, compiled by Dolphin Research. For an interpretation of the financial report, please refer to "Google's Dramatic Reversal: From AI 'Sacrifice' to AI 'Trendsetter'." 1. Review of Core Financial Data 1.1 Consolidated Performance Revenue: $102.3 billion, up 16% year-over-year (15% growth at constant currency). 2. Total Revenue Costs: $41.4 billion, up 13%. 3. Technology Costs: $14.9 billion, up 8%. 4. Other Revenue Costs: $26.5 billion, up 16%, primarily due to increased YouTube content procurement costs...
GoogleFinancial Analysis

Open: --
High: --
Low: --
Prev. Close: --
Volume: --
Turnover: --
Avg Price: --
Bid/Ask Ratio: --
Amplitude: --
52wk High: --
Volume Ratio: --
Turnover Ratio: --

HCA Healthcare Analyst Rating

Forecast & Rating

Jul 24, 2026

Price forecast

$467.2022.24%

Forecast & RatingBuy

25analysts

Strong buy52.00%
Buy4.00%
Hold40.00%
Sell4.00%
Strong sell0.00%

Daily Events

Jul, 24
HCA Healthcare closed at $382.19, up 1.5% from the previous close of $376.50, on the day of its Q2 earnings release. The stock experienced significant intraday volatility, declining in early morning trading to a low of $364.67 at 07:34 ET amid guidance cut expectations, before surging to an intraday peak of $398.51 at 10:13 ET on strong Q2 results, ultimately settling back toward the closing price. Q2 revenue grew 8.7% year-over-year to approximately $19.2 billion, and earnings per share increased 11% YoY, while the company declared a dividend of $0.78, signaling solid operational momentum. However, management's downward revision of full-year guidance—attributable to payer mix pressures from Medicaid reductions and declining surgical volumes—partially offset the positive earnings surprise. Notably, rival Tenet Healthcare surged 23% the same day, highlighting market differentiation between healthcare service providers. From a valuation perspective, HCA trades at a trailing PE of 12.58 with a market cap of $85.4 billion. The stock is down 18.75% year-to-date and trades 31.33% below its 52-week high of $556.52, currently below both the 20-day moving average of $390.41 and the 60-day moving average of $395.96.
Jul, 23
HCA Healthcare staged a strong rebound to $376.50 today, touching $384 during post-market hours and outperforming healthcare peers. The rally follows a challenging period: the Q2 earnings report triggered a sharp selloff as management cut 2026 profit guidance due to payer mix shifts and elective surgery volume declines, sending shares down over 32% from the 52-week peak of $556.52. Year-to-date decline stands at roughly 20%, with the stock now trading clearly below its 20-day moving average of $390.65 and 60-day average of $396.78. Analysts responded by cutting their price target to $486.6, which still implies about 25% upside from current levels. Today's bounce may reflect a reversal from extreme pessimism—investors appear to view the bad news as substantially priced in—though the fundamental headwinds of depressed surgical volumes and unfavorable payer mix remain unresolved.
Jul, 22
HCA Healthcare traded mixed today with premarket strength failing to persist through the regular session. After rising 0.51% to $375 during premarket, the stock opened at $374.39 and reached an intraday high of $377 at 10:15 ET, but closed at $371.87, down 0.33% from prior close of $373.09, and further weakened to $371.31 in extended hours. Year-to-date performance has been notably weak, with the stock down 20.94% and trading 33.18% below its 52-week high of $556.52. The stock trades significantly below its 20-day moving average of $391.21 and 60-day moving average of $397.94, reflecting technical weakness. The recent decline stems from the company's guidance reduction for 2026 earnings, driven by lower surgical volumes in Q2 and unfavorable payer mix shifts, raising concerns about near-term profitability. Despite solid Q1 2026 fundamentals with EPS of $7.15 (up 10.85% YoY) and revenue of $19.109 billion (up 4.3% YoY), analysts cut their 12-month price target to $486.6, implying only 25% upside from current levels. While the current P/E ratio of 12.24x appears attractive, the recent guidance reduction has dampened investor sentiment and limited near-term recovery catalysts.
Jul, 21
HCA Healthcare bounced to $373.09 on Monday (+0.72% intraday), extending gains to $375 in post-market trading, as investors digested Friday's downturn—when the company slashed 2026 earnings guidance following Q2 surgical volume declines and adverse payer mix shifts. Q1 revenues of $19.1 billion grew 4.3% year-over-year, yet net income barely expanded 0.62%, with net margin compressing from Q4's 9.62% to 8.48%, signaling operational pressure intensifying. Trading at a 12.3x P/E with $83.4 billion market cap, the stock has plummeted 33% from its 52-week high of $556.52 and is down 20.68% year-to-date, languishing below its 20-day and 60-day moving averages. Analysts subsequently trimmed the 12-month price target to $486.6, suggesting residual recovery potential yet underlying headwinds persist.
Jul, 20
HCA Healthcare traded mixed signals on July 20 following its recent Q2 earnings guidance cut, driven by a deteriorating payer mix and softer surgical volumes—indicating potential headwinds for the nation's largest hospital operator. Pre-market trading rallied sharply to $384.58 (+3.6% relative to the prior close), but midday selling pressure subsequently brought the stock down to $368.73 (−0.7%), with the regular session ultimately closing at $370.42, essentially flat versus the prior day. Post-market recovery to $375.58 suggested some bargain-hunting interest. From a technical perspective, the stock has retreated 33% from its March high of $556.52 and trades 21% below year-to-date levels, now positioned below both its 20-day ($392.16) and 60-day ($400.63) moving averages. Following the earnings revision, analysts cut their 12-month price target to $486.6, implying 25% upside potential, though the bull case remains contingent on stabilization in payer demographics and surgical procedure volumes.

News

Posts

Bullish vs. Bearish — Last 3 Months

819 followers · 0 opinions

FHW

▲Bullish50%

50%Bearish▼

D
Dolphin ResearchOct 30, 2025 at 01:18 AM
Google (Minutes): We are the only full-stack AI cloud platform
The following are the FY25 Q3 earnings call minutes for Google, compiled by Dolphin Research. For an interpretation of the financial report, please refer to "Google's Dramatic Reversal: From AI 'Sacrifice' to AI 'Trendsetter'." 1. Review of Core Financial Data 1.1 Consolidated Performance Revenue: $102.3 billion, up 16% year-over-year (15% growth at constant currency). 2. Total Revenue Costs: $41.4 billion, up 13%. 3. Technology Costs: $14.9 billion, up 8%. 4. Other Revenue Costs: $26.5 billion, up 16%, primarily due to increased YouTube content procurement costs...
GoogleFinancial Analysis

HCA Healthcare

HCA Healthcare

HCA Healthcare (HCA)

HCA Healthcare Analyst Rating

Forecast & Rating

Daily Events

News

Posts

Bullish vs. Bearish — Last 3 Months

Google (Minutes): We are the only full-stack AI cloud platform

HCA Healthcare (HCA)

HCA Healthcare Analyst Rating

Forecast & Rating

Daily Events

News

Posts

Bullish vs. Bearish — Last 3 Months

Google (Minutes): We are the only full-stack AI cloud platform